Evaluation of Efficacy of 2 Extended-release Bupivacaine Products in a Porcine Model of Incisional Pain
- PMID: 38508691
- PMCID: PMC11270038
- DOI: 10.30802/AALAS-JAALAS-23-000106
Evaluation of Efficacy of 2 Extended-release Bupivacaine Products in a Porcine Model of Incisional Pain
Abstract
Extended-release (ER) local anesthetics are often incorporated in multi-modal analgesia or as an alternative when the effect of systemic analgesics may confound research. In this study, we compared the analgesic efficacy of 2 ER bupivacaine anesthetics with different ER mechanisms, a slow-release bupivacaine-meloxicam polymer (BMP) and a sucrose acetate isobutyrate bupivacaine (SABER-B) system. We used a full-thickness unilateral skin incision porcine model to evaluate the efficacy of these 2 ER bupivacaine analgesics. Eighteen male swine were randomized into 3 groups: control (saline; n = 6), bupivacaine:meloxicam (10 mg/kg, 0.3 mg/kg; n = 6), and SABER-B (10 mg/kg; n = 6). After surgery, pigs were assessed for changes in body weight, salivary cortisol level, and response to von Frey testing at 1, 3, 6, 24, 48, 72, 96, 120, and 168 h. Body weight and salivary cortisol levels were not significantly different between groups. Based on the von Frey testing, the pigs that received analgesics showed a significantly higher withdrawal threshold of nociceptive stimulus than those that received saline at 1, 3, 6, and 24 h after the surgery. At 48 h after surgery, the SABER-B group had a significantly higher withdrawal threshold than the saline group. The withdrawal threshold was not significantly different from the baseline measurement on intact skin at 3 and 6 h after surgery in the BMP group or 1 and 3 h for the SABERB group. The analgesic effects of BMP were greatest at 3 and 6 h after surgery and that of SABER-B as 1 and 3 h SABER-B provided an earlier onset of analgesia and longer analgesia duration than did BMP. This study demonstrates that ER bupivacaine can provide pigs with 24 to 48 h of analgesia for incisional pain.
Conflict of interest statement
The author(s) have no conflict(s) of interest to declare.
Figures
Similar articles
-
Oxycodone for neuropathic pain and fibromyalgia in adults.Cochrane Database Syst Rev. 2014 Jun 23;(6):CD010692. doi: 10.1002/14651858.CD010692.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 Jul 28;7:CD010692. doi: 10.1002/14651858.CD010692.pub3. PMID: 24956205 Updated. Review.
-
Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.Health Technol Assess. 2022 Oct;26(44):1-310. doi: 10.3310/ZUCE8371. Health Technol Assess. 2022. PMID: 36321689 Free PMC article.
-
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.Cochrane Database Syst Rev. 2014 Apr 27;2014(4):CD007938. doi: 10.1002/14651858.CD007938.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2017 Jun 09;6:CD007938. doi: 10.1002/14651858.CD007938.pub4. PMID: 24771480 Free PMC article. Updated. Review.
-
Exploring zinc deficiency using serum Zn levels: consequences and potential solutions in suckling pigs.J Anim Sci. 2024 Jan 3;102:skad396. doi: 10.1093/jas/skad396. J Anim Sci. 2024. PMID: 38035764 Free PMC article.
-
Oral budesonide for induction of remission in ulcerative colitis.Cochrane Database Syst Rev. 2015 Oct 26;2015(10):CD007698. doi: 10.1002/14651858.CD007698.pub3. Cochrane Database Syst Rev. 2015. PMID: 26497719 Free PMC article. Review.
Cited by
-
Extended Release of Bupivacaine from Temperature-Responsive PNDJ Hydrogels Improves Postoperative Weight-Bearing in Rabbits Following Knee Surgery.Pharmaceuticals (Basel). 2024 Jul 3;17(7):879. doi: 10.3390/ph17070879. Pharmaceuticals (Basel). 2024. PMID: 39065729 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
